Exact Sciences (EXAS) News Today $45.59 +0.13 (+0.29%) Closing price 04:00 PM EasternExtended Trading$44.29 -1.30 (-2.85%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Price T Rowe Associates Inc. MD Grows Stake in Exact Sciences Co. (NASDAQ:EXAS)Price T Rowe Associates Inc. MD grew its stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 74.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,760,241 shares of the medical research company's stock afterApril 28 at 5:17 AM | marketbeat.comNebula Research & Development LLC Invests $3.28 Million in Exact Sciences Co. (NASDAQ:EXAS)Nebula Research & Development LLC acquired a new stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 58,439 shares of the medical research coApril 27 at 6:57 AM | marketbeat.comThis Exact Sciences Insider Increased Their Holding In The Last YearApril 26 at 9:50 AM | finance.yahoo.com13,520 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by Syon Capital LLCSyon Capital LLC purchased a new position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 13,520 shares of the medical research company's stock, valuApril 26 at 6:24 AM | marketbeat.comT. Rowe Price Investment Management Inc. Has $239.92 Million Position in Exact Sciences Co. (NASDAQ:EXAS)T. Rowe Price Investment Management Inc. raised its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 25.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,269,823 shApril 26 at 6:10 AM | marketbeat.comFirst Trust Advisors LP Decreases Stock Position in Exact Sciences Co. (NASDAQ:EXAS)First Trust Advisors LP trimmed its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 3.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 802,767 shares of the medical research company's stApril 26 at 4:56 AM | marketbeat.com101,173 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by Marshall Wace LLPMarshall Wace LLP bought a new stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 101,173 shares of the medical research company's stock, valued at approxApril 26 at 4:32 AM | marketbeat.comExact Sciences (EXAS) Projected to Post Earnings on ThursdayExact Sciences (NASDAQ:EXAS) will be releasing its Q1 2025 earnings after the market closes on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-exact-sciences-co-stock/)April 26 at 3:45 AM | marketbeat.comLeerink Partnrs Predicts Weaker Earnings for Exact SciencesExact Sciences Co. (NASDAQ:EXAS - Free Report) - Leerink Partnrs decreased their Q1 2025 earnings per share estimates for shares of Exact Sciences in a report released on Monday, April 21st. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will earn ($0.14) per shaApril 25 at 6:47 AM | marketbeat.comExact Sciences Co. (NASDAQ:EXAS) Position Increased by BI Asset Management Fondsmaeglerselskab A SBI Asset Management Fondsmaeglerselskab A S raised its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 662.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,290 shares of tApril 25 at 4:53 AM | marketbeat.com2 Reasons to Like EXAS (and 1 Not So Much)April 24, 2025 | finance.yahoo.comExact Sciences (EXAS): Among Billionaire George Soros’ Small-Cap Stocks with Huge Upside PotentialApril 24, 2025 | finance.yahoo.comLeerink Partnrs Forecasts Higher Earnings for Exact SciencesExact Sciences Co. (NASDAQ:EXAS - Free Report) - Analysts at Leerink Partnrs raised their Q3 2025 EPS estimates for shares of Exact Sciences in a research note issued to investors on Monday, April 21st. Leerink Partnrs analyst P. Souda now expects that the medical research company will earn $0.17April 24, 2025 | marketbeat.comQ3 EPS Estimates for Exact Sciences Increased by AnalystApril 24, 2025 | americanbankingnews.comLeerink Partnrs Expects Weaker Earnings for Exact SciencesApril 24, 2025 | americanbankingnews.comExact Sciences (NASDAQ:EXAS) Trading 5.7% Higher - Here's What HappenedExact Sciences (NASDAQ:EXAS) Trading Up 5.7% - What's Next?April 23, 2025 | marketbeat.comExact Sciences launches the Oncodetect MRD testApril 23, 2025 | markets.businessinsider.comRock Springs Capital Management LP Has $25.29 Million Stock Position in Exact Sciences Co. (NASDAQ:EXAS)Rock Springs Capital Management LP lowered its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 60.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 450,000 shares of the medical research company's stoApril 23, 2025 | marketbeat.comExact Sciences Launches New Test To Monitor Cancer Recurrence: Retail’s OptimisticApril 22, 2025 | msn.comExact Sciences Launches the Oncodetectâ„¢ Molecular Residual Disease TestApril 22, 2025 | businesswire.comExact Sciences Co. (NASDAQ:EXAS) Shares Bought by Thematics Asset ManagementThematics Asset Management lifted its position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 26.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 87,572 shares of the medicalApril 22, 2025 | marketbeat.comExact Sciences Co. (NASDAQ:EXAS) Shares Bought by Capital World InvestorsCapital World Investors boosted its position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 10.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,537,617 shares of the medicaApril 22, 2025 | marketbeat.comInvesco Ltd. Raises Position in Exact Sciences Co. (NASDAQ:EXAS)Invesco Ltd. lifted its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 57.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 379,683 shares of the medical research company's stock after purchasing an additional 138,089April 21, 2025 | marketbeat.comExact Sciences Co. (NASDAQ:EXAS) Holdings Cut by Blue Water Life Science Advisors LPBlue Water Life Science Advisors LP decreased its stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 69.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 78,843 shares of the medical research compaApril 20, 2025 | marketbeat.comAltium Capital Management LLC Acquires Shares of 100,000 Exact Sciences Co. (NASDAQ:EXAS)Altium Capital Management LLC bought a new position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 100,000 shares of the medical research company's stock, valued at approximApril 20, 2025 | marketbeat.comXTX Topco Ltd Reduces Position in Exact Sciences Co. (NASDAQ:EXAS)XTX Topco Ltd trimmed its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 55.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,217 shares of the medical research company's stock afterApril 20, 2025 | marketbeat.comCerity Partners LLC Has $1.54 Million Stake in Exact Sciences Co. (NASDAQ:EXAS)Cerity Partners LLC grew its stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 65.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,090 shares of the medical research company's stock after purchasingApril 20, 2025 | marketbeat.comExact Sciences Co. (NASDAQ:EXAS) Given Consensus Rating of "Moderate Buy" by AnalystsExact Sciences Co. (NASDAQ:EXAS - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-two research firms that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold rating, nineteen have given a buy rating aApril 20, 2025 | marketbeat.comChamplain Investment Partners LLC Reduces Holdings in Exact Sciences Co. (NASDAQ:EXAS)Champlain Investment Partners LLC reduced its stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 2.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,437,305 shares of the medical research company's stoApril 19, 2025 | marketbeat.comWasatch Advisors LP Has $23.48 Million Holdings in Exact Sciences Co. (NASDAQ:EXAS)Wasatch Advisors LP trimmed its stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 4.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 417,927 shares of the medical research company's stock after selling 19,9April 19, 2025 | marketbeat.comEnvestnet Asset Management Inc. Has $14.34 Million Stock Position in Exact Sciences Co. (NASDAQ:EXAS)Envestnet Asset Management Inc. lessened its stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 14.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 255,244 shares of the medicalApril 19, 2025 | marketbeat.comAdvisors Capital Management LLC Buys New Position in Exact Sciences Co. (NASDAQ:EXAS)Advisors Capital Management LLC purchased a new position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 9,157 shares of the medical researchApril 18, 2025 | marketbeat.comBernstein Reaffirms Their Buy Rating on Exact Sciences (EXAS)April 16, 2025 | markets.businessinsider.comAlliancebernstein L.P. Sells 890,747 Shares of Exact Sciences Co. (NASDAQ:EXAS)Alliancebernstein L.P. lessened its stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 92.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 69,845 shares of the medicalApril 16, 2025 | marketbeat.comLegal & General Group Plc Sells 280,642 Shares of Exact Sciences Co. (NASDAQ:EXAS)Legal & General Group Plc decreased its stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 37.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 461,608 shares of the medical research company's stock aApril 15, 2025 | marketbeat.comExact Sciences: Review in JAMA supports Oncotype DX Breast Recurrence Score testApril 14, 2025 | markets.businessinsider.com97,300 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by APG Asset Management N.V.APG Asset Management N.V. purchased a new position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 97,300 shares of the medical reseaApril 14, 2025 | marketbeat.comExact Sciences' (EXAS) "Buy" Rating Reiterated at GuggenheimGuggenheim reissued a "buy" rating and set a $60.00 price target on shares of Exact Sciences in a report on Friday.April 13, 2025 | marketbeat.comExact Sciences (NASDAQ:EXAS) Rating Increased to Strong-Buy at MizuhoMizuho upgraded Exact Sciences to a "strong-buy" rating in a research note on Wednesday.April 13, 2025 | marketbeat.comHarbert Fund Advisors Inc. Acquires Shares of 12,500 Exact Sciences Co. (NASDAQ:EXAS)Harbert Fund Advisors Inc. bought a new stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 12,500 shares of the medical research company's stock, valued at approximately $70April 13, 2025 | marketbeat.comKennedy Capital Management LLC Increases Stake in Exact Sciences Co. (NASDAQ:EXAS)Kennedy Capital Management LLC raised its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 10.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 147,459 shares of the medicalApril 13, 2025 | marketbeat.comDeep Dive Into Exact Sciences Stock: Analyst Perspectives (8 Ratings)April 12, 2025 | nasdaq.comExact Sciences (NASDAQ:EXAS) Price Target Cut to $55.00 by Analysts at BarclaysBarclays decreased their price objective on shares of Exact Sciences from $65.00 to $55.00 and set an "overweight" rating for the company in a research report on Thursday.April 12, 2025 | marketbeat.comMizuho Begins Coverage on Exact Sciences (NASDAQ:EXAS)Mizuho assumed coverage on Exact Sciences in a research note on Thursday. They issued an "outperform" rating and a $60.00 price objective for the company.April 12, 2025 | marketbeat.com103,651 Shares in Exact Sciences Co. (NASDAQ:EXAS) Bought by Aviva PLCAviva PLC acquired a new position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 103,651 shares of the medical research company's stock, valuedApril 12, 2025 | marketbeat.comResona Asset Management Co. Ltd. Purchases Shares of 53,784 Exact Sciences Co. (NASDAQ:EXAS)Resona Asset Management Co. Ltd. purchased a new stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 53,784 shares of the medical resApril 12, 2025 | marketbeat.comExact Sciences Co. (NASDAQ:EXAS) Shares Sold by Prudential Financial Inc.Prudential Financial Inc. decreased its position in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 46.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,089 shares of the medical research compApril 12, 2025 | marketbeat.comPrudential PLC Invests $483,000 in Exact Sciences Co. (NASDAQ:EXAS)Prudential PLC bought a new stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 8,594 shares of the medical research company's stock, valued at approximately $483,000. Other instApril 11, 2025 | marketbeat.comBarclays Sticks to Its Buy Rating for Exact Sciences (EXAS)April 11, 2025 | markets.businessinsider.comExact Sciences price target lowered to $55 from $65 at BarclaysApril 11, 2025 | markets.businessinsider.com Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Email Address EXAS Media Mentions By Week EXAS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EXAS News Sentiment▼0.830.85▲Average Medical News Sentiment EXAS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EXAS Articles This Week▼2910▲EXAS Articles Average Week Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Biogen News United Therapeutics News BioMarin Pharmaceutical News Incyte News Neurocrine Biosciences News Exelixis News Repligen News Halozyme Therapeutics News Madrigal Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EXAS) was last updated on 4/28/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EXAS Stock Free EXAS Stock Alerts